Market Overview

Spark Therapeutics Lacks Catalysts, Says Goldman Sachs

Share:
Spark Therapeutics Lacks Catalysts, Says Goldman Sachs
Related ONCE
Biotechs Were Innovators In 2018: Here Are The Top New Molecules That Were Approved
The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs

Goldman Sachs is downgrading Spark Therapeutics Inc (NASDAQ: ONCE) after the pharma startup presented disappointing data on its hemophilia A gene therapy at the annual meeting of the American Society of Hematology on Monday.

The Analyst

Goldman Sachs' Salveen Richter downgraded Spark Therapeutics from Buy to Neutral and lowered the price target to $58 from $106.

The Thesis

Sparks remains a leading gene therapy company, but it has limited value-driving catalysts in 2018, Richter said. (See Richter's track record here.) 

Goldman is projecting U.S. approval for Luxturna approval by Jan. 12, with a decent likelihood of a successful launch. There are also some preclinical assets that could enter clinic, like a liver disease-focused asset in-licensed from Genethon and drugs for Batten disease, Huntington's disease and the opthalmological disease Leber hereditary optic neuropathy, Richter said. 

The price target of Spark Therapeutics was calculated by averaging the sum-of-parts valuation of $70 and the discounted cash flow valuation of $45, Richter said. Goldman projects the takeover probability for Spark at zero to 15 percent. 

The Price Action

Spark's stock dropped around 35 percent Monday after the company presented weak hemophilia A gene therapy data. The stock was trading 1.68 percent lower at $45.14 at the time of publication. 

Related Links:

11 Biotech Stocks Moving From ASH 2017

Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates 

Latest Ratings for ONCE

DateFirmActionFromTo
Nov 2018Credit SuisseUpgradesUnderperformNeutral
Nov 2018WedbushUpgradesUnderperformNeutral
Nov 2018Raymond JamesUpgradesOutperformStrong Buy

View More Analyst Ratings for ONCE
View the Latest Analyst Ratings

Posted-In: Goldman Sachs Salveen RichterAnalyst Color Downgrades Price Target Analyst Ratings Best of Benzinga

 

Related Articles (ONCE)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
DESPKeyBancInitiates Coverage On0.0
MELIKeyBancInitiates Coverage On0.0
ALBKeyBancMaintains120.0
AVNSKeyBancMaintains67.0
ABTCredit SuisseInitiates Coverage On82.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Jefferies: M&A, Tax Reform Drive Vantiv Upside

How I Keep A Hot Trading Day From Going To My Head